U-REGN

Q:REGN - REGENERON PHARMACEUTICALS INC - http://www.regeneron.com

04:15:18 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
REGN - Q						612.49	+5.10	0.8	818.0	498,026	14,431	612.06 613.15 602.52	747.4214 523.2909	Jun 24	Jun 24	15 min RT 2¢

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market: Nasdaq -- Bid Tick: Down -- UPC Restricted: No

Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · 1yr Bulletins · Historical · Options · Portfolio

Recent Trades - Last 10 of 14431

Time ET	Ex	Price	Change	Volume

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Type	Headline
2022-06-24 07:31	U:REGN	News Release200	Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose
2022-06-07 16:44	U:REGN	News Release200	FDA Approves Dupixent(TM) (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
2022-06-02 07:30	U:REGN	News Release200	Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo(TM) (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer
2022-06-02 01:00	U:REGN	News Release200	Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment
2022-05-31 08:31	U:REGN	News Release200	Regeneron Completes Acquisition of Checkmate Pharmaceuticals
2022-05-31 00:59	U:REGN	News Release200	FDA Accepts Dupixent(TM) (dupilumab) for Priority Review in Adults with Prurigo Nodularis

Date ET

Symbol

Type

Headline

2022-06-24 07:31

U:REGN

News Release

Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose

2022-06-07 16:44

U:REGN

News Release

FDA Approves Dupixent(TM) (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis